- Home
- ANVS vs PSNL Comparison
ANVS vs PSNL Comparison
Compare ANVS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | PSNL |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 729.1M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANVS | PSNL |
|---|---|---|
| Price | $2.67 | $7.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $13.50 | $11.50 |
| AVG Volume (30 Days) | 338.3K | ★ 1.3M |
| Earning Date | 03-16-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | 33.58 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $16.94 |
| Revenue Next Year | N/A | $36.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $2.83 |
| 52 Week High | $5.50 | $11.50 |
Technical Indicators
Market Signals| Indicator | ANVS | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 41.03 |
| Support Level | $2.29 | $6.89 |
| Resistance Level | $2.63 | $9.64 |
| Average True Range (ATR) | 0.22 | 0.62 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 44.73 | 21.91 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.